Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...162163164165166167168169170171172...208209»
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Phase classification, Trial completion date, Trial primary completion date:  Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Dec 11, 2020   
    P2,  N=146, Not yet recruiting, 
    Patients with HER2-mutated, non-amplified metastatic breast cancers may benefit from pyrotinib. Phase classification: P2/3 --> P2 | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2025
  • ||||||||||  Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
    Enrollment open:  ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (clinicaltrials.gov) -  Dec 11, 2020   
    P3,  N=834, Recruiting, 
    Phase classification: P2/3 --> P2 | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2025 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Tomudex (raltitrexed) / Pfizer, AstraZeneca
    Journal:  Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways. (Pubmed Central) -  Dec 10, 2020   
    Western blot analysis showed that phosphorylation levels of Erk, Akt, and invasiveness-associated protein matrix metalloproteinases-9 (MMP-9) were decreased in the combination group. Taken together, these results indicate that raltitrexed enhances the antitumor effects of apatinib on human ESCC cells by down-regulating phosphorylation of Akt and Erk, implying a combination of raltitrexed and apatinib might be an effective option for treating esophageal squamous cell carcinoma patients.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    Trial primary completion date:  Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) -  Dec 10, 2020   
    P=N/A,  N=200, Recruiting, 
    Taken together, these results indicate that raltitrexed enhances the antitumor effects of apatinib on human ESCC cells by down-regulating phosphorylation of Akt and Erk, implying a combination of raltitrexed and apatinib might be an effective option for treating esophageal squamous cell carcinoma patients. Trial primary completion date: Dec 2022 --> Jan 2022
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. () -  Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_180;    
    P2
    26 patients (pts) with histologically confirmed stage ?/?/?a (cT2-4aN0-3M0) ESCC were enrolled from February 2020 to September 2020.The study was divided into two stages, stage1: we administered 1 cycle of Camrelizumab for induction therapy (200 mg q2 weeks); stage2: pts received 2 cycles of Camrelizumab (200 mg every 3 weeks) plus docetaxel and nedaplatin, followed by surgery within 4~6 weeks after neoadjuvant therapy completion. Camrelizumab in combination with preoperative chemotherapy followed by surgery for locally advanced ESCC showed promising downstaging effect and MPR with good tolerance, and its efficacy and safety could be further studied in later trials.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion date, Trial primary completion date, Metastases:  The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer (clinicaltrials.gov) -  Dec 9, 2020   
    P2,  N=48, Recruiting, 
    SCRT combined with subsequent CAPOX plus Camrelizumab followed by delayed surgery showed promising pCR rate with good tolerance in patients with LARC, regardless of the mismatch repair status, suggesting a candidate strategy for the neoadjuvant therapy. Trial completion date: Nov 2019 --> Dec 2021 | Trial primary completion date: Feb 2018 --> Dec 2020
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Trial completion date, Trial primary completion date:  OPAL2: A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) -  Dec 2, 2020   
    P2,  N=144, Recruiting, 
    Trial primary completion date: Mar 2021 --> Nov 2020 Trial completion date: Mar 2021 --> Oct 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open:  Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Nov 29, 2020   
    P2,  N=42, Recruiting, 
    Phase classification: P2 --> P=N/A Not yet recruiting --> Recruiting
  • ||||||||||  Conmana (icotinib) / Betta, fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
    Journal, PARP Biomarker:  The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells. (Pubmed Central) -  Nov 28, 2020   
    In the HCCC-9810 and GBC-SD human BTC cell lines, combined treatment with IH and FZ with synergetic radiation significantly inhibited cell proliferation, redistributed the cell cycle, enhanced apoptosis and delayed DNA damage repair by suppressing activation of the EGFR signaling pathway and attenuating expression of the homologous recombination (HR) protein RAD51. This study demonstrates that combined treatment with IH and FZ may be an applicable therapy to enhance the radiosensitivity of BTCs and that RAD51 may serve as a biomarker for this combination treatment.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Retrospective data, Journal:  Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis. (Pubmed Central) -  Nov 27, 2020   
    Apatinib was a viable treatment alternative for advanced NSCLC, as it offered a clinically meaningful and statistically significant improvement in PFS, ORR, and DCR. Moreover, therapy with apatinib did not significantly increase toxicity.
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Enrollment closed:  AMBER2: A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. (clinicaltrials.gov) -  Nov 25, 2020   
    P2,  N=164, Active, not recruiting, 
    A randomised controlled trial in locally advanced gastric or oesophagogastric junction adenocarcinoma is ongoing (ClinicalTrials.gov: NCT04208347). Recruiting --> Active, not recruiting